PK comparability study in case of non-linear PK [Regulatives / Guidelines]

posted by martin  – Austria, 2016-09-01 19:08 (3230 d 14:07 ago) – Posting: # 16620
Views: 2,137

Dear colleagues,

I would be happy to get the opinion from the forum members on the following topic:

- Reference product is administered as IV infusion
- Test product (modified formulation) is also administered as IV infusion

Challenge: Reference product indicates non-linear PK (MM).

Any ideas on the design of the PK comparability study (EU and US) taking the regulatory requirements into account would be highly appreciated.

Best regards

Martin

Complete thread:

UA Flag
Activity
 Admin contact
23,427 posts in 4,929 threads, 1,681 registered users;
48 visitors (0 registered, 48 guests [including 9 identified bots]).
Forum time: 09:15 CEST (Europe/Vienna)

No matter what side of the argument you are on,
you always find people on your side
that you wish were on the other.    Thomas Berger

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5